Roche (RHHBY,RO.SW) announced the CE Mark for its cobas BV/CV assay to identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media tube. The company said the cobas BV/CV assay delivers accurate and specific results, allowing healthcare professionals to deliver targeted therapies to patients more quickly. The cobas BV/CV assay is now available in countries accepting the CE Mark.
"The cobas BV/CV assay protects women from the risks of delayed or incorrect treatment, leading to faster relief from symptoms and a reduced likelihood of serious future complications," said Matt Sause, CEO of Roche Diagnostics.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.